On July 9, 2009, Der Spiegel, a respected and popular German news magazine, profiled a MAPS-sponsored clinical trial of LSD-assisted psychotherapy for people with anxiety associated with life-threatening illnesses. The LSD study is designed with an active dose of 200 mcg and an active placebo dose of 20 mcg.
Der Spiegel interviewed the principal investigator of the study, psychiatrist Peter Gasser, MD, and one of the subjects for the story. On July 24, 2009, the article was republished in English on Spiegel Online (this article is also archived in MAPS in the Media ). Peter and MAPS are pleased with the positive media coverage of the study. The study is still in the early stages of enrollment and we hope that the article will encourage people to apply to be subjects in the research. It is far too early for preliminary data analysis.